SCHEMBL2694972

SCHEMBL2694972

Cc1ccsc1CN1CC2(CCN(C(=O)c3ccc(CN(Cc4ncc[nH]4)Cc4ncc[nH]4)cc3)CC2)C1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 2/20 0.66
CYP3A4 P08684 14/20 0.42
CYP2D6 P10635 12/20 0.42
USP2 O75604 5/20 0.42
TSHR P16473 2/20 0.42
CYP2C9 P11712 7/20 0.42
CYP2C19 P33261 4/20 0.42
CYP1A2 P05177 3/20 0.42
ALOX15 P16050 1/20 0.42
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
MAPK1 P28482 1/20 0.38
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
HIF1A Q16665 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2694538 0.94 CXCR4 (0.67) CXCR4CYP3A4CYP2D6USP2TSHR
SCHEMBL2692055 0.94 CXCR4 (0.69) CXCR4CYP3A4CYP2D6USP2TSHR
SCHEMBL2692457 0.93 CXCR4 (0.70) CXCR4CYP3A4CYP2D6USP2TSHR
SCHEMBL2694147 0.89 CXCR4 (0.67) CXCR4CYP3A4CYP2D6USP2TSHR
SCHEMBL5930608 0.88 CXCR4 (0.62) CXCR4CYP3A4CYP2D6USP2TSHR
SCHEMBL2694083 0.87 CXCR4 (0.71) CXCR4CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2695171 0.87 CXCR4 (0.71) CXCR4CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL14103215 0.87 CXCR4 (0.62) CXCR4CYP3A4CYP2D6USP2TSHR
SCHEMBL2693825 0.86 CXCR4 (0.72) CXCR4CYP3A4CYP2D6USP2TSHR
SCHEMBL2694684 0.85 CXCR4 (0.59) CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US claimed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885CYP3A4 3747/4885CYP2D6 2687/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CXCR4 1/4885CYP3A4 4052/4885CYP2D6 2851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.